Litifilimab Shown to Reduce Number of Swollen Joints in Phase 2 Trial

Litifilimab (BIIB059), Biogen’s investigational antibody-based treatment for systemic lupus erythematosus (SLE), significantly reduced the number of swollen and tender joints in people with the autoimmune inflammatory disease over six months, new trial data show. With these positive results, the treatment candidate met the main goal of part A of the…